As a biotech company, there are multiple ways your innovative drug technology can add value and open opportunities for new drugs. In today’s business environment, it’s essential to explore business development opportunities across a range of deal structures, offering different value propositions to fit the different strategies of potential pharma partners. You may have a single drug asset that can be the centerpiece for a partnering deal. Or you might be seeking a platform deal focused on a therapeutic area or number of targets. This session will describe the different pathways to partnership by biotech executives who have successfully executed deals across a range of structures, as well as their present-day work on BD in their current roles.